Fig. 10

A, a Schematic of the immunological sequence of H-XL-MSN cancer vaccine to suppress tumor growth. b Level of SIINFEKL-specific CTLs in the lymph node. Seven days after vaccination (n = 4) (error bars, mean ± SD; **P < 0.0005). Reproduced with permission from Ref. [233] Copyright 2020, American Chemical Society. B Schematic illustration of the overall vaccination process using extra-large pore MSNs (XL-MSNs) loaded with antigen and TLR9 agonist to invoke antigen-specific cytotoxic T lymphocytes (CTLs) to suppress tumor growth. Reproduced with permission from Ref. [234] Copyright 2018, American Chemical Society. Further permissions related to this material excerpted should be directed to the ACS